Acer Therapeutics to Participate in January 2022 Virtual Investor Conferences
Acer Therapeutics Inc. (Nasdaq: ACER) announced participation in the upcoming 11th Annual LifeSci Partners Corporate Access virtual event and the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Acer Therapeutics Inc. (Nasdaq: ACER) announced participation in the upcoming 11th Annual LifeSci Partners Corporate Access virtual event and the H.C. Wainwright Global BioConnect Virtual Conference. The LifeSci event will feature one-on-one virtual meetings from January 5-7, 2022, while the H.C. Wainwright conference will present on-demand recordings on January 10, 2022. Acer focuses on developing therapies for serious rare diseases, with a diverse pipeline including ACER-001 for metabolic disorders and ACER-801 for induced vasomotor symptoms.
Details
News Market Reaction – ACER
The recorded move for ACER in the trading session of this news was +2.68%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEWTON, Mass., Dec. 22, 2021 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced that Acer’s management team will participate in the upcoming 11th Annual LifeSci Partners Corporate Access virtual event and the H.C. Wainwright BioConnect Virtual Conference.
| Conference: | 11th Annual LifeSci Partners Corporate Access virtual event |
| Format: | One-on-one virtual meetings |
| Dates: | January 5-7, 2022 |
| Register: | https://www.meetmax.com/sched/event_78427/invitee_login.html |
| Conference: | H.C. Wainwright Global BioConnect Virtual Conference |
| Format: | On-demand recorded corporate presentation |
| Dates: | January 10, 2022 |
| Webcast: | https://journey.ct.events/view/b30c9e23-05f3-4bc7-8e05-675b2cfa5a88 |
About Acer Therapeutics Inc.
Acer is a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs. Acer’s pipeline includes four programs: ACER-001 (sodium phenylbutyrate) for treatment of various inborn errors of metabolism, including urea cycle disorders (UCDs) and Maple Syrup Urine Disease (MSUD); ACER-801 (osanetant) for treatment of induced Vasomotor Symptoms (iVMS); EDSIVO™ (celiprolol) for treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1) mutation; and ACER-2820 (emetine), a host-directed therapy against a variety of infectious diseases, including COVID-19. Each of Acer’s product candidates is believed to present a comparatively de-risked profile, having one or more of a favorable safety profile, clinical proof-of-concept data, mechanistic differentiation and/or accelerated paths for development through specific programs and procedures established by the FDA. In March 2021, Acer entered into a Collaboration and License Agreement with Relief for development and commercialization of ACER-001. For more information, visit www.acertx.com.
Investor Contact:
Hans Vitzthum
LifeSci Advisors
Ph: 617-430-7578
hans@lifesciadvisors.com
Jim DeNike
Acer Therapeutics Inc.
Ph: 844-902-6100
jdenike@acertx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.